Combination regimens for other novel agents with romidepsin in PTCLs have also been explored: 1) The multiple mutations in epigenetic modifier genes (e.g., TET2, IDH2, and DNMT3A) and TCR-related genes (e.g., RHOA and FYN) may impair immunogenicity of PTCL and facilitate immune escape [62]. This evidence concerns the gene TET2 and mature T-cell and NK-cell non-Hodgkin lymphoma.